Hallucinogens
Hallucinogens
The term hallucinogen refers to a variety of substances capable of inducing profound altered states of consciousness. Also known as phantastica, psychedelics, entheogens, and psychointegrators, these substances have a long history of use in societies throughout the world.
The “major” hallucinogens are LSD, mescaline, psilocybin (found in “magic mushrooms”), and the tryptamine derivatives (found in ayahuasca). These substances alter sensory perception and produce changes in a person’s body image and awareness of space and time, but they do not cloud consciousness and have little impact upon memory. Persons typically remain fully aware of the effects as they are occurring and retain vivid memories afterwards. Although the chemical structures of these substances vary and their mechanisms of action are not yet fully understood, dopamine, serotonin, and norepinephrine receptor sites have been implicated in their activity. While Cannabis (“marijuana”) is sometimes included in this list, its effects and mechanism of action are distinct and involve other receptor sites.
The “minor” hallucinogens include anticholinergic substances (atropine and scopolamine) that block acetylcholine receptors. These produce relatively mild perceptual and cognitive changes, but they do cloud consciousness and impact memory, so that individuals may be unable to recall their experiences. The “psychedelic anesthetics” (ketamine and phencyclidine or PCP) affect NMDA receptors and induce profound dissociative effects.
The use of hallucinogens in traditional cultural settings has been extensively documented. These substances induce a hypersuggestible state that makes those who ingest them receptive to the messages received during initiation into adulthood and in religious rituals. Because the experiences are explained before they are induced, the effects are understood within a culturally defined and socially sanctioned framework that reassures the initiates and provides emphatic evidence of the “correctness” of the foundational premises of their society’s worldview.
Although traditional societies have been using hallucinogens for culturally constructive purposes for millennia, scientific interest in hallucinogens is comparatively recent. In the late 1800s, anthropological studies led to the recognition of the visionary effects of the peyote cactus. Subsequent research led to the isolation (1896) and synthesis (1919) of mescaline, the primary hallucinogenic component of peyote. Mescaline was thus the first hallucinogen to become available as a pharmaceutical preparation. The fantastic descriptions of the effects produced by mescaline attracted the attention of both scientists and artists, a pattern that would be repeated with other hallucinogens.
In 1938, Albert Hofmann, a Swiss chemist working at Sandoz Laboratories, first synthesized LSD (lysergic acid diethylamide) during his research into potential analgesics. During subsequent research in 1943, Hofmann accidentally ingested a miniscule amount of the drug (through the skin) and soon noticed marked perceptual changes and other effects. He then undertook a self-experiment using what he thought was an extremely small dose (250 micrograms) and experienced even more profound effects. Hofmann was later asked to identify the active constituents (psilocybin and psilocin) in samples of “magic mushrooms” (Psilocybe spp.) collected in Mexico. Uncertain of their usefulness and desiring to determine if there was a market for these substances, Sandoz made LSD (under the name Delysid) and psilocybin (known as Indocybin) available for psychiatric, therapeutic, and experimental research.
During the 1950s and early 1960s, considerable scientific research was conducted into hallucinogens. In clinical settings, these substances showed promise in treating chronic alcoholism, psychological trauma, pain, and obsessive-compulsive disorders. The U.S. and British governments also investigated the potential of hallucinogens as agents of chemical and psychological warfare. In the 1950s and 1960s, the CIA, in a project known as MKUL-TRA, gave scopolamine, mescaline, LSD, psilocybin, and other agents to numerous individuals, often without their knowledge. The unpredictability of the effects and the suicide of several subjects led to the termination of this work.
As knowledge about the visionary effects and therapeutic potential of the hallucinogens became more widespread, numerous artists, writers, and scientists had “psychedelic” experiences that profoundly affected their work. One of the first was Aldous Huxley (1894–1963), whose experiences with mescaline led him to write The Doors of Perception (1954) and Heaven and Hell (1956), two essays that introduced hallucinogens to the public. Another influential figure was the Harvard psychologist Timothy Leary (1920–1996), who first encountered psilocybin mushrooms during a trip to Mexico in 1960. Leary subsequently obtained a large quantity of psilocybin from Sandoz and began to offer it to other Harvard faculty and graduate students. With his team, he also administered psilocybin to violent criminals, with promising results.
Leary and others also investigated the effects of hallucinogens upon artists, musicians, and other creative individuals. As the circle of people who had had an experience with a hallucinogen expanded, increasing numbers of individuals became interested in these substances. Eventually, “acid tests,” “be-ins,” and other events provided the opportunity for thousands of people to simultaneously experience the effects of a hallucinogen. For many, the inner worlds revealed by these substances offered a stark contrast to consumerism, the push to conform, and the war in Vietnam. “Psychedelic” music, art, and poetry gave expression to these experiences, challenged conventional morality and authority, and led to the emergence of a “counterculture” that maintained that peace, love, and “flower power” could change human consciousness and alter the political landscape. In the late 1960s, governments reacted by enacting laws prohibiting the use, possession, manufacture, and distribution of most hallucinogens. While this did curtail some illicit use, it also put a stop to legitimate research.
Scientific research with human subjects resumed in the 1990s. In pilot studies, hallucinogens have been administered to terminal patients to help them confront their impending death, and they have been used to treat victims of post-traumatic stress disorder and sufferers of cluster headaches. The ancient tradition of hallucinogen use within a religious context is continued in the Native American Church, which uses peyote, and by several Brazilian churches (including the Santo Daime and União de Vegetal [UDV]) that use ayahuasca. These religious movements have achieved great success in helping their members overcome addictions to alcohol and other drugs, and they are legally allowed to use specific hallucinogens as “sacraments.”
In 1999, U.S. Customs agents seized a shipment of ayahuasca that had been shipped to the United States for use by an American chapter of União de Vegetal. The government claimed that the mixture contained substances banned by U.S. and international law. However, a 2006 U.S. Supreme Court decision unanimously affirmed that the government had not demonstrated a compelling interest in prohibiting the UDV from using ayahuacsa in their religious services, thereby allowing them to use it legally in the United States.
Increased recognition that hallucinogens can be used for constructive purposes has led to renewed calls to review and, where appropriate, reduce the legal restrictions on these substances. In the United States, mescaline, LSD, psilocybin, psilocin, and even Cannabis are currently categorized as Schedule I substances, which are defined as having a high potential for abuse, a lack of acceptable safety when used under medical supervision, and a lack of currently accepted medical use. Similar restrictions exist internationally. However, these legal classifications are not consistent and are rarely adjusted as new scientific findings and patterns of illegal use become known. In many jurisdictions, drug classification often reflects political and social trends rather than scientific data. For example, in the United States the major hallucinogens are listed in Schedule I along with heroin, a substance that is available to physicians and patients in Europe. In contrast, methamphetamine, one of the most addictive and personally destructive drugs known, is classified as a Schedule II drug with a currently acceptable medical use. Moreover, many experts consider alcohol and tobacco to have a much greater potential for both personal and social harm than any of the hallucinogens (including Cannabis ).
The 2003 National Survey on Drug Use & Health estimated that 34,363,000 Americans (14.5% of the population) had used a hallucinogen (excluding Cannabis ) at least once in their lives. The same survey estimated that 96,611,000 persons (40.6%) had used Cannabis at least once. Worldwide, the United Nations Office on Drugs and Crime (UNODC) reported in 2006 that approximately 162,400,000 people used Cannabis in 2005 (3.9% of the total world population between the ages of 15 and 64). The UNODC did not report on the prevalence of LSD, peyote, or mescaline use.
In contrast to heroin and methamphetamine and the legal drugs ethyl alcohol and nicotine, hallucinogens (including Cannabis ) are not physically addictive, and such substances as LSD, mescaline, and psilocybin even exhibit cross-tolerance with one another, meaning that daily dosages quickly lose their effectiveness. Both the traditional patterns of use and the increasing scientific evidence that many of the major hallucinogens can be useful in treating various disorders and in personal growth, and that Cannabis is an effective remedy for glaucoma, pain, the side effects of chemotherapy, and for many other purposes, demonstrates that a rethinking of drug laws in general, and the potential roles of hallucinogens in particular, is long overdue.
SEE ALSO Drugs of Abuse; Leary, Timothy; Native Americans; Psychotropic Drugs
BIBLIOGRAPHY
Julien, Robert M. 2005. A Primer of Drug Action. 10th ed. New York: Worth Publishers.
Nutt, David, Leslie A. King, William Saulsbury, and Colin Blakemore. 2007. Development of a Rational Scale to Assess the Harm of Drugs of Potential Misuse. The Lancet. Vol. 369, March 24, 2006, pp. 1047–1053.
Rätsch, Christian. 2005. The Encyclopedia of Psychoactive Plants. Trans. John R. Baker. Rochester, VT: Park Street Press.
Stevens, Jay. 1987. Storming Heaven: LSD and the American Dream. New York: Atlantic Monthly Press.
United Nations Office on Drugs and Crime. 2006. World Drug Report. New York: United Nations. http://www.unodc.org/unodc/world_drug_report.html.
U.S. Substance Abuse and Mental Health Services Administration (SAMHSA). 2003. National Survey on Drug Use & Health. Washington, DC: SAMHSA. http://www.drugabusestatistics.samhsa.gov/.
Winkleman, Michael J., and Thomas B. Roberts, eds. 2007. Psychedelic Medicine: New Evidence for Hallucinogenic Substances as Treatments. Westport, CT: Praeger.
John R. Baker
